The new SARCLISA J-code J9227 is now available, effective October 1, 2020, to be used for reimbursement claims. Refer to the Billing and Coding Guide on the Resources page for additional details. MAT-US-2018558-v1.0-08/2020

Trial Results

Demonstrated Efficacy With SARCLISA + Pd vs Pd Alone

SARCLISA + Pd extended median PFS to ~1 year1

Superior PFS with SARCLISA + Pd vs Pd alone1

The median duration of treatment was 41 weeks with SARCLISA + Pd vs 24 weeks with Pd. 1

At a median follow-up time of 11.6 months, 43 patients (27.9%) receiving SARCLISA + Pd and 56 patients (36.6%) receiving Pd had died. Median OS was not reached for either treatment group at interim analysis. The OS results at interim analysis did not reach statistical significance. 1

ORR: SARCLISA + Pd (95% CI: 52.2%, 68.2%), Pd (95% CI: 27.8%, 43.4%). 95% CI estimated using the Clopper-Pearson method.

Median time to first response was 35 days with SARCLISA
+ Pd vs 58 days with Pd alone among responders1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Category 1, Preferred recommendation for isatuximab-irfc (SARCLISA)

Isatuximab-irfc (SARCLISA), in combination with pomalidomide and dexamethasone, is a Category 1, Preferred option for previously treated multiple myeloma by the National Comprehensive Cancer Network® (NCCN®).2

Back to topTop Safety